We are witnessing a perfect example of how pharma’s hogs are going to get slaughtered
|11/10/2017||Posted by BusinessMediaguide.Com under General World News||
- At a luncheon Thursday, Mallinckrodt Pharma executives said at least one big payer has started putting restrictions on its $36,000-a-dose drug called Acthar, a person in attendance told Business Insider.
- Express Scripts, the giant pharmacy benefit manager, says it is recommending prior authorization for up to a 30-day supply.
- Continued formulary restrictions could force Mallinckrodt to continue raising the price of Acthar, which would only make payers even angrier.
Mallinckrodt Pharmaceuticals was absolutely destroyed in the market this week after reporting earnings on Tuesday.
The stock fell as much as 35% on the news that something was keeping prescriptions of the company’s blockbuster $36,000-a-dose read more >>>